國立虎尾科技大學 |

Preserving the promise : = improving the culture of biotech investment /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Preserving the promise :/ Scott Dessain, MD, PhD, Scott E. Fishman, MA.
Reminder of title:	improving the culture of biotech investment /
Author:	Dessain, Scott,
other author:	Fishman, Scott E.,
Description:	1 online resource (x, 265 pages) :illustrations (some color) :
Subject:	Biotechnology. -
Online resource:	https://www.sciencedirect.com/science/book/9780128092163
ISBN:	9780128092095

Preserving the promise : = improving the culture of biotech investment /
Dessain, Scott,MD, PhD,

Preserving the promise :improving the culture of biotech investment /Scott Dessain, MD, PhD, Scott E. Fishman, MA. - 1 online resource (x, 265 pages) :illustrations (some color)

Includes bibliographical references and index.

8 Out of the Frying Pan: The Fire's Not So Great EitherJuggling Interest, Support, Commitment, and IP; A Fulcrum of Tension; The Special Case of Conflict of Interest; References; 9 Getting to Australia; Reaching the Limits; References; Translation Gap 1: Universities Don't Make What Companies Need; 10 When Is an Experiment Ready for the Valley of Death?; Why Not Simply License the Technology to a Big Healthcare Company?; Collaboration and Conflict; References; 11 Unintended Consequences of Applying for a Patent; The Dollars Begin to Flow; The Real Costs of a Patent Application; References.

"Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This 'Valley of Death' squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of 'conventional wisdom' that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. Explains why translation of biotech discovery into medicine succeeds so infrequently that it's been dubbed the Valley of Death. Uncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patients. Examines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologies. Deconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better."--Provided by publisher.

ISBN: 9780128092095Subjects--Topical Terms:

554955
Biotechnology.
Index Terms--Genre/Form:

554714
Electronic books.

LC Class. No.: HD9999.B442 / D47 2017

Dewey Class. No.: 338.476606

Preserving the promise : = improving the culture of biotech investment /
LDR:05361cam a2200325 i 4500 001 949090
006 m o d
007 cr mn|||||||||
008 200620s2017 enka ob 001 0 eng d
020 $a 9780128092095 $q (electronic bk.)
020 $a 0128092092 $q (electronic bk.)
020 $a 9780128092163
035 $a (OCoLC)960447973 $z (OCoLC)960493468 $z (OCoLC)960834522 $z (OCoLC)965147652 $z (OCoLC)965414362
035 $a els69900533
040 $a YDX $b eng $e rda $e pn $c YDX $d N$T $d IDEBK $d EBLCP $d N$T $d GZM $d OPELS $d OCLCF $d IDB $d OCLCQ $d NHM $d OCLCQ $d CSAIL $d OCLCQ $d VGM $d OCLCQ $d MERUC
041 0 $a eng
050 4 $a HD9999.B442 $b D47 2017
082 0 4 $a 338.476606 $2 23
100 1 $a Dessain, Scott, $c MD, PhD, $e author. $3 1237888
245 1 0 $a Preserving the promise : $b improving the culture of biotech investment / $c Scott Dessain, MD, PhD, Scott E. Fishman, MA.
264 1 $a London : $b Academic Press, $c [2017]
300 $a 1 online resource (x, 265 pages) : $b illustrations (some color)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
504 $a Includes bibliographical references and index.
505 8 $a 8 Out of the Frying Pan: The Fire's Not So Great EitherJuggling Interest, Support, Commitment, and IP; A Fulcrum of Tension; The Special Case of Conflict of Interest; References; 9 Getting to Australia; Reaching the Limits; References; Translation Gap 1: Universities Don't Make What Companies Need; 10 When Is an Experiment Ready for the Valley of Death?; Why Not Simply License the Technology to a Big Healthcare Company?; Collaboration and Conflict; References; 11 Unintended Consequences of Applying for a Patent; The Dollars Begin to Flow; The Real Costs of a Patent Application; References.
505 8 $a 12 What if It Doesn't Actually Work?References; 13 Building a Better Mousetrap; References; Translation Gap 2: Good Innovation Is Not Always a Good Investment; 14 Due Diligence and Angel Incentives; How Angels Decide; Due Diligence-An Overview; Due Diligence-Getting Specific; Exogenous Factors; Unmet Clinical or Professional Need; Size and Growth of the Addressable Market; Adaptability of the Technology or Product to Clinical Practice; Potential for Sustainable Competitive Advantage; References; 15 What Is Value?; Attractiveness and Plausibility of the Technology.
505 8 $a Likelihood that Clinical Proof of Concept is AchievableChallenges of the Regulatory Environment; Attractiveness of the Business Model; Financial Viability; Exit Strategy; Human Resources and Contingency Planning; Reflections on Due Diligence; So Where is Big Pharma/Big Biotech on All This? A Breakdown in Value; References; 16 Angels at the Crux of Invention; Bad Stuff Gets Funded and Good Stuff Dies; The Uncertainty of Scientific Due Diligence; Investing to the Next Money; References; 17 Investment: A Nuanced Decision; References.
505 8 $a 18 Ready for a Long-Term Relationship With a Science Experiment?Due Diligence Versus De-Risking; Financing the Biotechnology Start-up; Buying and Selling in the VoD; The Perils of Convertible Debt; References; 19 Investing in Hockey Sticks; The Hockey Stick-A Matter of Inflection; Milestone Driven Investments; The Perfect Deal; ROI Versus Innovation; References; 20 Harps for Angels; Consideration of the Macro Environment; Regional, Economic, and Cultural Influences; References; 21 Connecting Innovation to Investment; Reducing the Risk of Scientific Failure; Rewarding the Long Game; References.
520 $a "Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This 'Valley of Death' squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of 'conventional wisdom' that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. Explains why translation of biotech discovery into medicine succeeds so infrequently that it's been dubbed the Valley of Death. Uncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patients. Examines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologies. Deconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better."--Provided by publisher.
650 0 $a Biotechnology. $3 554955
650 0 $a Biotechnology industries $x Finance. $3 679353
650 0 $a Pharmaceutical industry $x Finance. $3 1237890
655 4 $a Electronic books. $2 local $3 554714
700 1 $a Fishman, Scott E., $e author. $3 1237889
856 4 0 $u https://www.sciencedirect.com/science/book/9780128092163